Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 2Terminated 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 141Thoracic 63Genitourinary 37Lymphoid 34Breast 25Gynecologic 24Sarcoma 14Tumor-Agnostic 13Head & Neck 8Other hematologic neoplasm 6Dermatologic 6Other solid neoplasm 5Plasma cell 2Myeloid 2CNS 2

Conditions

Myeloproliferative Disorders 2Multiple Myeloma 2Breast Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 49fludarabine phosphate 41fludarabine 36Azacitidine 34Busulfan 30Whole-Body Irradiation 26Antilymphocyte Serum 24Tacrolimus 23Imatinib Mesylate 23Mycophenolic Acid 22Cytarabine 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16thymoglobulin 14venetoclax 13Granulocyte Colony-Stimulating Factor 13Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Gemcitabine × Myeloid × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡